Sirtris Pharmaceuticals to Present at the National Institute of Aging on December 4, 2007
Posted on: Monday, 3 December 2007, 09:00 CST
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that on December 4, 2007 it will be presenting at the National Institute of Aging Workshop on Aging.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the potential therapeutic effects of SIRT1 activators for diseases of aging, such as Type 2 Diabetes and disorders, such as MELAS, the progress and results of pre-clinical studies of SIRT1 activators, and the potential of sirtuin modulators to receive regulatory approval. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company's product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company's potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
Source: Business Wire
Related Articles
- Sirtris Pharmaceuticals Presents at the American Diabetes Association's 68th Annual Scientific Sessions June 8
- Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model
- Sirtris Pharmaceuticals Enters Collaborative Study Testing New Chemical Entities and Clinical Drug Candidate In Multiple Models of Cancer With the National Cancer Institute
- Sirtris Pharmaceuticals' Oral Drug Candidate SRT501 Shown To Be Neuroprotective
- Sirtris Pharmaceuticals and Sirtuin Academic Thought Leaders Publish Review on the Therapeutic Potential of Sirtuins for Diseases of Aging
- Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
- Sirtris Pharmaceuticals to Present at the FASEB Summer Research Conferences
- Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
- Sirtris Pharmaceuticals To Present at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
- Sirtris Pharmaceuticals Named As One of the ''Fierce 15'' Biotech Companies of 2007
 |
 |
User Comments (0)
RSS Feeds